HC Wainwright Has Negative Forecast for MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.18) per share for the quarter, down from their previous forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.02) EPS.

Milestone Pharmaceuticals Trading Down 2.0 %

NASDAQ:MIST opened at $1.95 on Thursday. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $2.75. The company has a market cap of $104.04 million, a P/E ratio of -2.41 and a beta of 1.83. The business has a 50 day moving average price of $2.02 and a two-hundred day moving average price of $1.81.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its stake in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares in the last quarter. National Bank of Canada FI increased its position in Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares during the last quarter. Atria Investments Inc raised its stake in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after buying an additional 12,430 shares during the period. PVG Asset Management Corp acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $46,000. Finally, Northern Trust Corp increased its holdings in shares of Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after acquiring an additional 30,772 shares during the last quarter. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.